SHOCKING: John vandermosten | Mind Blowing Facts

ALLR: A Precision Undertaking

By John Vandermosten, CFA NASDAQ:ALLR READ THE FULL ALLR RESEARCH REPORT

Benzinga · Sep 13, 2022

ACOGF: Bioequivalence Complete

By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT

Benzinga · Sep 7, 2022

ALQGC: FRESH Results in November

By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT

Benzinga · Sep 6, 2022

DYAI: Dapibus on the Menu

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT

Benzinga · Aug 16, 2022

ECOR: Consistent Expansion of Distribution

By John Vandermosten, CFA NASDAQ:ECOR READ THE FULL ECOR RESEARCH REPORT

Benzinga · Aug 10, 2022

LEXX: Put Your Drinks Up! Four Deals Signed in June

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT

Benzinga · Aug 8, 2022

MDXG: 2Q:22 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT

Benzinga · Aug 4, 2022

BIOAF: FY 2022 Results and Valuation Update

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

Benzinga · Aug 2, 2022

BCTX: New Sites Expand Bria-IMT Trial

By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT

Benzinga · Jun 28, 2022

ACOGF: Resolving to Move Ahead

By John Vandermosten, CFA OTC:ACOGF READ THE FULL ACOGF RESEARCH REPORT

Benzinga · Jun 28, 2022